1008P - Concurrent chemoradiation with weekly gemcitabine and cisplatin in locally advanced carcinoma of the head and neck

Date 29 September 2014
Event ESMO 2014
Session Poster Display session
Topics Anticancer Agents
Head and Neck Cancers
Surgical Oncology
Biological Therapy
Radiation Oncology
Presenter Smriti Gaur
Citation Annals of Oncology (2014) 25 (suppl_4): iv340-iv356. 10.1093/annonc/mdu340
Authors S. Gaur, S..S. Kumar, P. Balasubramanian
  • Dept. Of Radiation Oncology, Madras Medical College, 600003 - Chennai/IN



To assess immediate locoregional response to concurrent chemoradiation with gemcitabine and cisplatin in locally advanced head and neck cancer and to assess the toxicity.


30 patients of stage 3 and 4 squamous cell carcinoma of head and neck were taken for this single arm prospective study .They were treated with gemcitabine 20mg/m2 and cisplatin 30mg/m2 once a week, concurrent with radiotherapy in a conventional fractionated manner of 2Gy per fraction, up to a total of 70Gy, 5 days a week, completed in 7 weeks. The response to treatment and acute toxicity were assessed clinically, during treatment and after 4-6 weeks of treatment. Toxicities were graded using RTOG acute morbidity criteria and CTCAE criteria.


The complete and partial response rates were 80% and 20%, respectively. 46% had grade 1 haematological toxicity. No renal toxicity was seen. 73.3% had grade 3 mucositis, 16% from grade 2. 36.6% showed grade 3 skin reaction. Compared with concurrent chemoradiation with weekly cisplatin, this study showed an increase in complete response (80% vs 60%), but an increase in mucosal toxicity was also seen, which was statistically significant.


Concurrent chemoradiation with weekly gemcitabine and cisplatin shows promising results with slightly high but manageable toxicity. However, randomized trials are needed in future to further validate this regimen.


All authors have declared no conflicts of interest.